(HealthDay News) — Prostate-specific antigen (PSA) screening likely results in a reduction in prostate cancer-specific mortality, according to a review published online May 15 in the Cochrane Database ...
Stephen Freedland, MD, of Cedars-Sinai, discussed enzalutamide and leuprolide's potential to improve overall survival without sacrificing quality of life in prostate cancer. In patients with high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results